Fulgent Genetics Reports Promising Phase 2 Results for FID-007 in Head and Neck Cancer
Reuters
Oct 20
Fulgent Genetics Reports Promising Phase 2 Results for FID-007 in Head and Neck Cancer
Fulgent Genetics Inc. has announced preliminary clinical data from its ongoing phase 2 trial investigating FID-007 in combination with cetuximab for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). The data, with a cutoff date of September 25, 2025, will be presented at the European Society for Medical Oncology (ESMO) conference in Berlin, Germany, on October 20, 2025. In the study, 39 patients were randomized and 36 received at least one dose of treatment. FID-007 combined with cetuximab showed an objective response rate of 44% in the 75 mg/m2 arm and 59% in the 125 mg/m2 arm, with an overall response rate of 51%. Median progression-free survival was 9.2 months for the lower dose and 7.8 months for the higher dose, compared to a historical standard-of-care median of 2.3 months. The combination treatment exhibited a favorable safety and tolerability profile, with a 6% rate of treatment-related serious adverse events. The optimal dose of FID-007 will be determined after further data maturation.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251020009581) on October 20, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.